Alterations in dihydropyrimidine dehydrogenase gene (DPYD) coding for the key enzyme (DPD) of fluoropyrimidines (FPs) catabolism contribute to the development of serious FPs-related toxicity. We performed mutation analysis of DPYD based on cDNA sequencing in 76 predominantly colorectal cancer patients treated by FPs with early development of high (grade 3-4) hematological and/or gastrointestinal toxicity. Six previously described [85T>C (C29R), 496A>G (M166V), 775A>G (K259E), 1601G>A (S534N), 1627A>G (I543V), IVS14+1G>A, 2194G>A (V732I)] and two novel [187A>G (K63E) and 1050 G>A (R357H)] non-synonymous DPYD variants were found in 56/76 (73.7%) high-toxicity patients. Subsequently, these alterations were analyzed in 48 patients with excellent long-term tolerance of FPs and in 243 controls and were detected in 37/48 (77.1%) and 166/243 (68.3%) cases, respectively. Analysis of these alterations as risk factors for development of toxicity in pooled FPs-treated population demonstrated that C29R negatively correlated with overall gastrointestinal toxicity (OR = 0.48; 95%CI 0.23-1.0) and M166V in women protected against overall hematological toxicity and neutropenia (both OR = 0.26; 95%CI 0.07-0.89), whereas IVS14+1G>A (found in five high-toxicity patients only) increased risk of mucositis in overall population (OR = 7.0; 95%CI 1.1-44.53), and thrombocytopenia in women (OR = 10.8; 95%CI 1.24-93.98). Moreover, we identified a strong association of V732I with leucopenia (OR = 8.17; 95%CI 2.44 -27.31) and neutropenia (OR=2.78; 95% CI 1.03-7.51). Our data enabled characterization of "high risk" haplotypes (carriers of IVS14+1G>A or V732 lacking M166V) representing small (22% female and 11% male patients), population in high risk of serious hematological toxicity development, and in patients with "lower risk" that unlikely develop serious hematological toxicity [carriers of M166V without IVS14+1G>A and V732I in females (32% women), and non-carriers of C29R, M166V, IVS14+1G>A, and V732I in males (46% men)]. Our results indicate that genotyping of several DPYD variants may lead to stratification of patients with respect to the risk of serious hematological toxicity development during FPs treatment.
(DPYS; OMIM 222748; EC 3.5.2.2) and finally β-ureidopropionase (UPB1; OMIM 606673; EC 3.5.1.6) converting fluoro-β-ureidopropionate to fluoro-β-alanine excreted in urine [3, 4] . Dihydropyrimidine dehydrogenase is ubiquitously expressed cytosolic enzyme with a high activity in the liver and mononuclear lymphocytes [5] . The dihydropyrimidine dehydrogenase gene (DPYD; OMIM 274270) consists of 23 exons distributed approximately over 900 kbp region of 1p22 [6, 7] . The DPD protein sequence is highly conserved among different species. The DPD molecule consists of 1025 amino acids (111 kDa) and it is organized in five functional domains [8] . The prosthetic groups involving one FAD, one FMN and four [4Fe-4S] promote electron transport during the redox reactions [9] . Physiologically, DPD homodimer catalyzes the first step in pyrimidine degradation: the NADPH-dependent reduction of uracil and thymine to the corresponding 5,6-dihydropyrimidines.
Serious 5-FU toxicity responsible for treatment discontinuation and death in some patients typically occurs in form of high-grade hematological and non-hematological complications (neutropenia, thrombocytopenia, diarrhea, stomatitis, and hand-foot syndrome). These adverse events results from increased bioavailability of 5-FU caused by decreased 5-FU catabolism in the liver tissue due to inherited decreased capacity of 5-FU catabolism or of liver function impairment. Both homozygotes and heterozygotes carrying mutations in DPYD altering structure of the enzyme were shown to have decreased 5-FU catabolism [10] . Over 50 different sequence variants of DPYD were described in patients with severe toxicity following 5-FU treatment so far, and several of them are referred to as disease-causing gene alterations [10] [11] [12] . Despite the widely accepted disease-causing mutations (e.g. IVS14+1G>A), the biological effect of many, mainly missense variants (e.g. M166V or C29R) remained controversial [13] [14] [15] [16] [17] .
To address the contribution of DPYD alterations to the development of severe toxicity in 5-FU-treated patients we performed the mutation analysis of DPYD involving two extreme populations: patients with high-grade or life-threatening toxicity developed at the beginning of drug application vs. patients with very good tolerance of 5-FU treatment without any signs of major toxicity within long-lasting treatment period.
Patients and methods
Study design. Our retrospective pharmacogenomic study involved the two cancer patients' populations treated by fluoropyrimidine-containing regimens. The first one (termed "high-toxicity group") consisted of cancer patients developing high-grade (Grade 3-4; National Cancer Institute of Canada Common Toxicity Criteria scale; NCIC CTC) hematological (leucopenia, neutropenia or thrombocytopenia) toxicity and/or gastrointestinal (mucositis, emesis, diarrhea) toxicity during the first or the second cycle of 5-FU treatment. Dermatological adverse events were not considered to be indicative for selection of the high-toxicity patients [18, 19] . The second population (termed "low-toxicity group") involved patients with a high tolerance to 5-FU treatment. All individuals in this group received at least ten consecutive cycles of 5-FUbased chemotherapeutic regimens without development of hematological or gastrointestinal toxicity (i.e. the toxicities were evaluated as Grade 0-1 according to NCIC CTC). Patients with inadequate liver function tests were not enrolled to prevent biased 5-FU clearance. The population frequency of characterized DPYD alterations was analyzed in representative group of control population. The DPYD mutation analysis was performed in the high-toxicity group by bi-directional sequencing of DPYD mRNA (cDNA) isolated from peripheral blood lymphocytes. Only DPYD exons harboring alterations of coding sequence characterized in the high-toxicity group were subsequently analyzed in the low-toxicity group and the control population by DHPLC (Denaturing High-Performance Liquid Chromatography).
The primary endpoints of our study involved characterization of DPYD gene coding sequence alterations in 5-FU treated patients and analysis of haplotype(s) predisposing to the development of serious site-specific toxicity in 5-FUtreated patients.
Patients and genetic material. The high-toxicity group consisted of 76 individuals who were reported to develop serious toxicity (NCIC CTC Grade 3-4 toxicity) attributable to 5-FU during the first or second cycle of fluoropyrimidines-based therapy (Tab. 1). Five out of 76 high-toxicity patients (9.2%) died for the fatal toxic reactions (four with grade 4 hematological toxicities and one with gastrointestinal grade 4 toxicity). A total of 104 patients were recruited from oncology centers in the Czech Republic between January 2002 and May 2008, following signature of informed consent approved by ethical committee. Clinical characteristics were obtained via Internetbased form organized by Comprehensive Oncology Center (www.koc.cz) [20, 21] . Each case reported by on-line formulary was reviewed by co-operating experienced oncologists' team to fulfill criteria of the high toxicity clearly attributable to 5-FU therapy. The oncologists' review board excluded 28 patients including 14 not fulfilling inclusion NCIC CTC criteria of high-toxicity, 5 patients treated by 5-FU containing regimens previously, and 9 patients with incomplete documentation.
The low-toxicity group included 48 individuals with excellent tolerance of 5-FU therapy (NCIC CTC Grade 0-1 toxicity) treated by more than ten cycles of fluoropyrimidines-based regimens (Tab. 1). Fifty-three patients were enrolled at the Departments of Oncology, Faculty Hospitals in Prague and Pilsen between April 2003 and July 2007. During re-evaluation of clinical data, five individuals were discharged from low-toxicity group due to presence of the toxicity higher than grade 0-1.
The non-cancer control population (103 males and 140 females), aged 55.7 ± 17.0 years (mean ± SD), consisted of randomly selected adult persons examined at the Department of Clinical Biochemistry and Laboratory Medicine, General Teaching Hospital in Prague between January 2003 and No-vember 2005, excluding those with primary cancer diagnosis (Tab. 1). All patients and controls were Caucasians from the Czech Republic.
Total RNA was extracted from blood samples obtained only from high-toxicity patients. The blood samples were preserved in PAX Gene collection tubes (BD Diagnostics) and RNA was isolated using PAX Gene Blood RNA kit (Qiagen) according to manufacturers protocols. The blood samples for DNA isolation in EDTA-containing collection tubes (BD Diagnostics) were obtained from all individuals. Genomic DNA was isolated using Wizard DNA isolation kit (Promega) according to manufacturer.
Mutation analysis of the DPYD gene. Mutation analysis of entire DPYD coding region in high-toxicity patients' samples was performed by sequencing of cDNA. Two µg of total RNA was used for cDNA synthesis with 5U of SuperScriptIII Reverse Transcriptase (Invitrogene) and 150 pmol of random hexanucleotides (Roche) under the manufacturer instruction. Whole coding sequence of DPYD mRNA (including flanking 5' and 3' UTRs) was amplified in three overlapping fragments using 2.5 µl of cDNA, 0.5 U Gold Taq polymerase (Applied Biosystems), 0.5 µl 50xdNTP's (Invitek), 2.5 µl 10x Gold Taq PCR buffer (Applied Biosystems), 0.75 µl 50 mM MgCl 2 , and 3 pmol of each PCR primer (Generi-Biotech; Tab. 2) in 25μl volume. The PCR protocol consisted of denaturation at 96°C for 10 min, followed by 34 cycles (30 s at 95°C, 45 s at 68°C and 2 min at 72°C), and final extension at 72°C for 10 min. Purified PCR products (JETQUICK PCR Product Purification Spin Kit; Genomed) were sequenced on ABI3130 analyzer (Applied Biosystems) using BigDye Terminator Mix ver. 3.1 (Applied Biosystems) and primers listed in Tab. 2. All DPYD alterations characterized by cDNA sequencing were confirmed by sequencing of genomic DNA (Tab. 3).
Only the exons (Tab. 3), in which alterations of coding sequence occurred in the high-toxicity patients' samples, were analyzed in samples from the low-toxicity and control population groups. Amplicons covering exons and flanking intron sequences were PCR amplified in 25 μl volume containing 100 ng gDNA, 0.25 U Gold Taq DNA polymerase, 0.5 µl 50xdNTP's 2,5 µl 10x Gold Taq PCR buffer and 30 pmol of each PCR primer under conditions specified in Tab. 3. Following denaturation/ renaturation step, 5 μl PCR aliquots were subjected to DHPLC analysis (WAVE 3500 System; Transgenomic) under conditions specified in Tab. 3. The amplicons covering DPYD exons 2 and 18 were reanalyzed by DHPLC Statistical analyses. The odds ratios (OR) and 95% confidence intervals (CI) of OR were computed for determination the risks factors between investigated groups. As alternative of logistic regression, the Chi-Square test was used. The relations between the investigated parameters were computed by the Spearman correlation coefficients. The comparison of variables in given groups and subgroups, considering to the distribution of this variables, was performed by a non-parametric Wilcoxon test. All statistical analyses were performed using CRAN 2.4.0. software (http://www.r-project.org/). For genotype-phenotype correlations, the individual toxicities in pooled high-and lowtoxicity groups were analyzed as individual variables (mucositis, diarrhea, emesis, leucopenia; neutropenia; thrombocytopenia), and also as the overall gastrointestinal or the overall hematological toxicity numerically equal to the highest grade of particular toxicity in a given group.
Genotype frequencies in the analyzed populations were estimated using chi-square test in Linkage Disequilibrium Analyzer (LDA) 1.0 software [22] .
Results

DPYD alterations in the group of high-toxicity patients.
The DPYD cDNA sequencing enabled fast screening of variants within coding sequence and alterations affecting DPYD mRNA splicing (e.g. IVS14+1G>A) in the group of hightoxicity cancer patients. At least one gene alteration affecting DPD protein composition was found in 56 out of 76 (73.7%) samples in this group.
Two novel DPYD missense variants [c.187A>G (p.K63E) and c.1050 G>A (p.R357H)] were found, each occurring as the only DPYD alteration in two high-toxicity patients (Fig. 1) . The c.187A>G transition leads to change of a highly conservative lysine 63 to glutamate (K63E; data not shown) localized within exclusively α-helical domain I containing two Fe-S clusters [8] . The homology modeling (Fig. 1A ) based on crystallography data of porcine DPD enzyme (93% identity to human homologue) indicates the proximity of lysine 63 to FAD binding site in domain II [8, 14] . The change of lysine 63 to negatively charged glutamate might therefore influence the electron transfer pathway. The second newly described transition c.1050G>A causes replacement of less conservative arginine 357 to histidine (data not shown), however, the in silico modeling of this alteration ( Fig. ˝1B) showed that the missense mutation affects the outer loop protruding outside from the NADPH binding domain III and hence the possibility of significant alteration of DPD protein structure is probably low. This hypotheses support the results of Align GVGD missense mutation predictive tool (http://agvgd. iarc.fr/index.php; data not shown) classifying the K63E to high-risk Class C55 with risk 2.5-3.0, whereas the R357H was classified in low risk Class C0 with risk 0.9 -1.1 [23] .
The c.1905+1G>A (IVS14+1G>A) mutation resulting in exon 14 skipping was found in five out of 76 (6.6%) high- were detected in two and four out of 76 high-toxicity patients, respectively (Tab. 4). We did not find any significant differences in frequencies of mutations between male and female high-toxicity patients.
DPYD alterations in the group of low-toxicity patients and control population. The exons carrying non-synonymous changes in the high-toxicity group were analyzed in 48 samples from the low-toxicity cancer patients group and 243 samples from non-cancer controls using DHPLC. This analysis revealed 37 carriers of at least one DPYD alteration in the group of 48 (77.1%) low-toxicity patients (Tab. 4). Exon 14 skipping mutation (IVS14+1G>A) and rare missense variants (K63E, K259E, and R357H) were not detected in any of the low-toxicity patient. The significant differences were found in frequencies of C29R carriers [26/76 (34.2%) of high-toxicity vs. 26/48 (54.2%) of low-toxicity patients; p = 0.03]. The significant difference was found in frequency of M166V within the low-toxicity group between males (12/23; 52.2%) and females (6/25; 24.0%; p = 0.04). Compared to high-toxicity patients, the significant difference was found in female subgroup for frequency of C29R carriers [12/40 (30.0%) of high-toxicity vs. 14/23 (60.9%) of low-toxicity female patients; p = 0.02] and M166V carriers [10/40 (25.0%) of high-toxicity vs. 12/23 (52.2%) of low-toxicity female patients; p = 0.03].
Analysis of control population identified 166 out of 243 individuals (68.3%) carrying at least one DPYD gene alteration (Tab. 4) with no difference in frequencies of particular alterations between males and females. Statistically significant difference between controls and the high-toxicity group was found in frequency of IVS14+1G>A carriers The DHPLC analysis performed in the low-toxicity and control groups revealed presence of five intronic variants flanking to analyzed exons (IVS9-51T>G, IVS10-15T>C, IVS12-11G>A, IVS13+39C>T, and IVS13+40A>G). All these variants of unknown significance were described previously in various populations and were not considered for further analysis in our study [12, 24, 25] . The strong association of IVS13+39C>T with c.1627A>G (I543V) reported in previous studies was also observed in our samples (data not shown) [16, 26] .
DPYD haplotypes in analyzed populations. All variants detected in DPYD coding sequence in three analyzed populations were in Hardy-Weinberg equilibrium (p>0.05), with the only exception for I543V (p = 0.02) in the low-toxicity group. Identified were 46 different haplotypes encompassing all alterations affecting DPYD coding sequence (Tab. 5). The strongest statistically significant linkage was apparent between C29R and M166V (R = 0.425; p<0.0001) in the all analyzed populations.
Contribution of individual DPYD coding sequence alterations to the development of serious 5-FU toxicity. The overall gastrointestinal and hematological toxicity, as well as individual toxicities were analyzed as phenotypes potentially affected by individual DPYD coding sequence alterations in the pooled group (N = 124) including all cancer patients from the highand low-toxicity groups. The logistic regression analysis revealed that several DPYD missense variants may negatively or positively influence risk of toxicity development in the overall populations or in the males and females subgroups, respectively. A protective effect was shown for two alterations -c.85T>C (C29R) and c.496A>G (M166V), whereas carriers of c.1905+1G>A (IVS14+1G>A) and c.2194G>A (V732I) were at significantly higher risk of serious site-specific toxicity development (Fig. 2) . No association was found for c.1601G>A (S534N), c.1627A>G (I543V), and rare DPYD alterations. The novel DPYD variants c.187A>G (K63E) and c.1050 G>A (R357H) were found only in one woman (with neutropenia grade 4 and diarrhea grade 3) and one man (with diarrhea grade 4), respectively. Rare alteration c.775A>G (K259E), reported previously twice in high-and low-toxicity German patients, respectively, was found in combination with C29R and V732I in one man (with leucopenia grade 3 and neutropenia grade 4) [14, 27] .
Carriers of TC or CC mutant allele (C29R) showed 2.1-times lower risk (OR = 0.48; Fig. 2 ) for development of overall serious gastrointestinal toxicity (grade 0-2 vs. 3-4) comparing to the patients carrying wild type (TT) allele. This protective effect of mutated allele C29R was even stronger considering patients developing gastrointestinal toxicity grade 0-2 vs. 4 (OR = 0.19; 95% CI = 0.04 -0.96; p = 0.04). A borderline statistical significance was shown for the female carriers of C29R comparing to that carrying wild-type allele in a protection against overall hematological toxicity development (grade 0-2 vs. 3-4; OR = 0.35; 95% CI = 0.12 -1.08; p = 0.07), however, we found significant difference in this group analyzing high-grade hematological toxicity grade 0-2 vs. 4 (OR = 0.21; 95% CI = 0.05 -0.86; p = 0.03). Similarly, carrying of at least C29R allele protected with borderline statistical significance neutropenia The IVS14+1G>A, found only in one man and four women in the high-toxicity group, was associated with significantly higher risk of mucositis development in the overall patients population and female subgroup (OR = 7.0 and OR = 10.62, respectively; Fig. 2 ). The carriers of IVS14+1G>A in overall population showed statistically insignificant trend toward development of overall hematological toxicity (OR = 8.9), neutropenia (OR = 9.2), and thrombocytopenia (OR = 5.9; for all grade 0-2 vs. 3-4 p <0.07). However, this mutation increased the risk of high-grade hematological toxicity (grade 0-2 vs. 4) in the whole population (OR = 11.3; 95% CI = 1.21 -105.36; p = 0.03). In the female subpopulation, carriers of IVS14+1G>A were in high risk of thrombocytopenia (grade 0-2 vs. 3-4 OR = 10.8; Fig. 2) , and considering the most serious toxicity grade 0-2 vs. 4, the risk of thrombocytopenia development was even higher (OR = 27.0; 95% CI = 1.20 -605.59; p = 0.04).
The missense alteration V732I conferred a risk factor mainly of hematological toxicities development. It significantly increased the risk of leucopenia (grade 0-2 vs. 3-4) in the whole cancer patients' population (OR = 8.2) and in men The impact of analyzed categories on serious toxicity development was performed by logistic regression analysis involving all patients treated by 5-FU-containing regimens with grade 0-2 vs. 3-4 (consisted of the pooled high-and low-toxicity groups) separated according to selected allelotypes (Fig. 3) . Because the risk of toxicity development differed between men and women in our study as well as in previously published trials with 5-FU treated patients, we performed this analysis with respect to the gender groups [27, 19] .
Female patients included in "high risk" category (category 1) were at significantly increased risk of leucopenia (OR = 9.4) and thrombocytopenia (OR = 6.13) compared to other women (categories 2+3+4; Fig. 3 ). This category showed a trend toward increased risk of neutropenia and overall hematological toxicity (for both OR = 3.02; 95% CI = 0.89 -10.24; p = 0.08) compared to other women (categories 2+3+4; Fig. 3) . Male "high-risk" patients (category 1) had increased risk of leucopenia (OR = 16.67), neutropenia (OR = 8.75) and overall hematological toxicity (OR = 7.88) compared to other men (categories 2+3+4; Fig. 3) .
Only "lower risk" female patients (category 2) tended to decrease risk of neutropenia and overall hematological toxicity (for both OR = 0.32; 95% CI = 0.09 -1.10; p = 0.07) compared to other women (categories 1+3+4; Fig. 3 ). This category was of no significant importance in the male subgroup.
Wild-type female patients (category 3) did not show any decreased risk for development of hematological toxicities. Moreover, the significant association was found for increased risk of serious emesis (grade 0-2 vs. 
Discussion
The influence of DPD on tolerance of 5-FU-based therapy is widely accepted [10, 28] . However, the involvement of other genetic factors [e.g. downstream enzymes of 5-FU degradation pathway -DPYS and UBP1, or other enzymes -thimidylate synthetase (TYMS; OMIM 188350) or methylenetetrahydrofolate reductase (MTHFR; OMIM 607093)] to the development of fluoropyrimidines-related toxicity has been also considered [27, [29] [30] [31] . Since eighties, the numerous methods based on determination of DPD status were advised to predict serious 5-FU-related toxicity. The function tests have been used for measurement of DPD enzyme activity by 2-[ [32] [33] [34] . Substantial drawbacks of function tests are a need for specialized technology approaches or the use of radiolabeled chemicals not available worldwide [34] . The other strategy, used also for prediction of treatment efficacy, involves the expression analyzes of DPD by immunohistochemistry or at the level of mRNA [35] [36] [37] . Despite its easiness, many contradictory results regarding the predictive power of expression analyses were obtained [38, 39] . The influence of DPYD promoter methylation on DPYD gene expression was also considered, however contrary to initial reports latest studies demonstrated limited or no methylation of DPYD promoter in high-toxicity patients [27, [40] [41] [42] . The most common concept for prediction of serious toxicity in 5-FU-treated patients represents pharmacogenomic analyses. Numerous DPYD alterations were reported in published studies and case reports, however the vast majority represents missense gene variants with unknown impact on DPD enzyme activity. Moreover, the strong population differences in frequency of common DPYD gene alterations and haplotypes were described [12] . Recently, the common fragile site FRA1E was localized in DPYD gene, however the large deletions in DPYD were not studied so far [43] . Combinatory approaches implementing functional and expression analyses alongside to genotyping introduced by Morel et al. (2006) could enhance specificity and sensitivity of 5-FU toxicity detection, however it seems to be less suitable for routine clinical settings [44] . Therefore, despite substantial effort, there is currently unavailable a simple and reliable test predicting serious toxicity following 5-FU treatment [45, 46] .
In our current survey, we studied the DPYD variants in patients suffering from high-grade 5-FU-related toxicity (hightoxicity patients) comparing to the patients with superior tolerance of fluoropyrimidines-based therapy (low-toxicity patients). We performed the genotyping of DPYD variants in the whole coding sequence in 76 high-toxicity patients and we detected the splicing site mutation IVS14+1G>A and eight different missense variants including two previously undescribed. The splicing mutation IVS14+1G>A was found in similar frequency in our high-toxicity patients (6.6%) compared to that in recent prospective German study (5.5%) published by Schwab et al. (2008) , however, contrary to this study we did not find any low-toxicity patient carrying this alteration [27] . The frequency of IVS14+1G>A carriers in our control population of the Czech origin is relatively high (2.1%), comparing to that found in overall or cancer patients populations in the Central European region: Slovakia (0%), Poland (0.4%), Germany (1.1%) [47, 48] and exceeding the frequency in the Netherlands (1.8%) were the IVS14+1G>A testing has been advised for clinical utilization prior 5-FU therapy [49, 50] .
For the two novel rare variants, each detected in patient with high toxicity, we hypothesize that c.187A>G (K63E) may potentially interfere with DPD enzymatic activity, but the c.1050G>A (R357H) could less likely influence the DPD enzyme function according to the prediction models of DPD protein structure. All non-synonymous DPYD changes that were found in 73.7% of high-toxicity patients were screened in low-toxicity patients group and non-cancer controls, where they were found in 77.1% and 68.3% of samples, respectively.
Our results demonstrated that missense alterations C29R, M166V, S534N, I543V, and V732I representing the vast majority of detected variants are highly frequent DPYD polymorphisms in our population. Except the C29R and M166V, which we found in significantly higher frequency in the lowtoxicity patients group, the frequency of others (S534N, I543V, and V732I) did not significantly differ between high-and lowtoxicity patients and therefore, they can not be considered the causative factors of overall 5-FU toxicity. We found the strong segregation of C29R with M166V in our study population.
Further, we tested the frequency of analyzed mutations and polymorphisms in relationship to the frequencies of hematological and gastrointestinal toxicities in the pooled population of 124 patients treated by fluoropyrimidines. The C29R mutation represented mild (OR = 0.48) independent protective factor for overall gastrointestinal toxicity in the whole population, detected in 31/61 (51%) patients with gastrointestinal toxicity grade 0-2 and 21/63 (33%) of patients with gastrointestinal toxicity grade 3-4. We found that in women population the M166V mutation negatively correlated with overall hematological toxicity and neutropenia (OR = 0.26). For both toxicities, carriers of M166V accounted for 18/40 (45%) patients with toxicity grade 0-2 and 4/23 (17%) patients with toxicity grade 3-4. Contrary to this result, recent German study involving 89 patients with good and 39 patients with poor tolerance of fluoropyrimidines-based chemotherapy published by Gross et al. (2008) described the positive correlation of M166V with development of grade 3-4 fluoropyrimidine toxicity (OR = 4.42) in patients with gastroesophageal and breast cancer, but without significance for colorectal cancer patients [26] . Several differences in the design of studies could contribute to this contradictory results, including the higher proportion of the high-toxicity patients' population and more frequent colorectal cancer diagnoses in our study. Interestingly, the supplementary data from the other recent German multicenter prospective trial published by Schwab et al. (2008) involving patients treated by 5-FU monotherapy reported the allelic frequency of M166V as 8/60 (13%) and 10/108 (9%) for patients with toxicity grade 0-2 and 3-4, respectively, however, the effect of M166V itself was not evaluated in this study [27] . The two independent genetic factors positively correlating with toxicity in our study represented IVS14+1G>A and V732I. The IVS14+1G>A contributed to higher risk of mucositis development in overall population and mucositis and thrombocytopenia in women subgroup, however, these results need to be interpreted with caution, as only five carriers of this alterations in high-grade toxicity patients (four women) were detected in our study. The carriers of V732I alteration, that has been considered the polymorphism [16] , were relatively frequent in our study and at significantly higher risk for neutropenia development. We found this alteration in 7/14 (50%) and in 12/110 (11%) patients with neutropenia grade 3-4 and 0-2, respectively. Moreover, all carriers of V732I in the high-grade neutropenia patients group suffered from neutropenia grade 4 and two of them (both women) were with lethal outcome, following 5-FU or capecitabine in monotherapy. The presence of V732I significantly positively correlated also with development of thrombocytopenia in overall population, leucopenia and neutropenia in men and leucopenia in women. The aforementioned study of Schwab et al. (2008) found the frequency V732I as 38/1,146 (3.3%) alleles in patients with grade 0-2 fluorouracil toxicity and 14/220 (6.4%) alleles in patients with grade 3-4 toxicity [27] . The allelic frequency of V732I in study of Gross et al. (2008) did not differed between 89 no/mild toxicity and 39 grade 3-4 toxicity patients (0.10 and 0.09, respectively) [26] .
Based on our results reflecting significant associations of several DPYD gene variants with particular site-specific toxicities differing in gender groups, we determined haplotypes considering possible protective effects of C29R and M166V and negative effects of IVS14+1G>A and V732I for development of fluoropyrimidines-related toxicity. The strongest significance we observed for the "high risk" patients category (carriers of IVS14+1G>A or V732 lacking M166V) represented by limited populations 14/63 (22%) women and 7/61 (11%) men, but identified in 4/6 (66%) female and 4/8 (50%) male patients with leucopenia grade 3-4, 8/23 (35%) female and 5/17 (29%) male patients with neutropenia grade 3-4, as well as in 4/7 (57%) female and 2/7 (29%) male patients with thrombocytopenia. The category described as the "lower-risk" (carriers of M166V allele without IVS14+1G>A and V732I mutations) displayed limited insignificant trend for protective role in female population only. Females carrying this haplotypes accounted for 20/63 (32%) from all female patients, but this haplotypes occurred only in 4/23 (17%) of women with neutropenia (or overall hematological toxicity) grade 3-4. On the other hand, the protective role of "wild-type" category (non carriers of C29R, M166V, IVS14+1G>A, and V732I) was observed in the male patients group consisting of 28/61 (46%) male patients. Male carriers of these haplotypes were found in only 1/8 (13%) of men with grade 3-4 leucopenia, in 5/17 (29%) men with grade 3-4 neutropenia, and in 5/18 (28%) men with overall hematological toxicity.
Despite these promising results we are aware that any clinical interpretation of our study should be performed with caution and confirmation of our results by further prospective trial involving the new unsorted fluoropyrimidine-treated patients, that may also resolved the sensitivity and specificity, and hence the usefulness this concept is essential. This ongoing independent study should verify if using this fast and easy analysis implementing genotyping of the only four DPYD gene variants (C29R, M166V, IVS14+1G>A, and V732I) may discriminate male and female patients recruiting from our "high risk" category in whom the fluoropyrimidines dose reduction or alternative treatment regimes application should be a priori considered, together with patients with "lower risk", that may benefit from regular fluoropyrimidines therapy with favorable safety profile. If these results will be proved, there would be also the time for reconsideration of biological rationale of alterations in DPYD. Despite the high frequency of genetic variants in DPYD, only little of them (representing relatively small portion of the high-toxicity patients' population) exert clear effect leading to abrogation of DPD enzyme activity and most of DPYD variants are polymorphisms with no easily apparent influence on development of serious toxicity. Further studies analyzing the large fluoropyrimidine-treated patients' populations as well as in vitro analyses with human tissue cultures and experiments on animal models are desired to clarify the role of these DPYD variants. Finally, our data indicate that the development of serious toxicity in fluoropyrimidine-treated patients may not only differ in men and women subpopulations, but the site-related toxicity should be also considered.
